The announcement of Esperion Therapeutics' projected operating expenses for FY24, especially the significant portion allocated to non-cash stock compensation, could lead to concerns about increased operational costs and its impact on profitability. This may result in a negative short-term impact on the stock price as investors reassess the company's future earnings potential and cost management strategies.